Advaxis Price to Book Ratio 2007-2021 | ADXS

Historical price to book ratio values for Advaxis (ADXS) over the last 10 years. The current price to book ratio for Advaxis as of October 22, 2021 is 1.54.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Advaxis Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 0.47 1.54
2021-07-31 0.41 $0.30 1.35
2021-04-30 0.49 $0.33 1.50
2021-01-31 0.73 $0.32 2.26
2020-10-31 0.34 $0.39 0.87
2020-07-31 0.58 $0.50 1.16
2020-04-30 0.67 $0.59 1.14
2020-01-31 0.86 $0.69 1.25
2019-10-31 0.32 $0.79 0.40
2019-07-31 0.56 $2.56 0.22
2019-04-30 3.54 $5.38 0.66
2019-01-31 5.69 $8.06 0.71
2018-10-31 8.42 $5.19 1.62
2018-07-31 21.90 $9.46 2.31
2018-04-30 24.00 $12.97 1.85
2018-01-31 44.40 $13.92 3.19
2017-10-31 51.00 $19.74 2.58
2017-07-31 97.05 $27.19 3.57
2017-04-30 128.40 $34.10 3.77
2017-01-31 134.40 $40.06 3.36
2016-10-31 121.35 $44.65 2.72
2016-07-31 125.10 $36.34 3.44
2016-04-30 116.10 $41.64 2.79
2016-01-31 102.30 $46.47 2.20
2015-10-31 166.35 $51.62 3.22
2015-07-31 249.90 $46.43 5.38
2015-04-30 252.15 $25.82 9.77
2015-01-31 147.75 $19.60 7.54
2014-10-31 47.70 $15.76 3.03
2014-07-31 42.60 $17.88 2.38
2014-04-30 40.80 $21.58 1.89
2014-01-31 67.35 $15.90 4.24
2013-10-31 56.10 $19.67 2.85
2013-07-31 52.50 $-20.59 -2.55
2013-04-30 131.25 $-20.56 -6.38
2013-01-31 131.25 $-29.87 -4.39
2012-10-31 93.75 $-28.31 -3.31
2012-07-31 131.25 $-24.97 -5.26
2012-04-30 243.75 $-77.02 -3.16
2012-01-31 281.25 $-74.37 -3.78
2011-10-31 262.50 $-94.13 -2.79
2011-07-31 281.25 $-95.12 -2.96
2011-04-30 393.75 $-192.12 -2.05
2011-01-31 281.25 $-99.13 -2.84
2010-10-31 281.25 $-140.04 -2.01
2010-07-31 318.75 $-217.31 -1.47
2010-04-30 412.50 $-288.27 -1.43
2010-01-31 262.50 $-248.75 -1.06
2009-10-31 243.75 $-254.98 -0.96
2009-07-31 168.75 $-221.04 -0.76
2009-04-30 93.75 $-21.74 -4.31
2009-01-31 75.00 $-9.25 -8.10
2008-10-31 75.00 $-14.39 -5.21
2008-07-31 112.50 $4.95 22.71
2008-04-30 281.25 $25.28 11.12
2008-01-31 281.25 $49.30 5.70
2007-10-31 375.00 $74.09 5.06
2007-07-31 468.75 $-172.30 -2.72
2007-04-30 637.50 $-216.18 -2.95
2007-01-31 300.00 0.00
2006-07-31 337.50 0.00
2006-04-30 487.50 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.068B $0.000B
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76